StreetAlpha.app
Home › Stocks › ENTX

Entera Bio Ltd. (ENTX)

Healthcare
$3.31
▲ +0.76%
LAST CLOSE · NOV 20

Entera Bio develops oral tablet versions of injectable peptide and protein medicines, starting with an osteoporosis candidate. It last closed at $3.31 on Nov 20, up 0.76% on the day. The next earnings report for ENTX is expected around Fri, Mar 26, 2027, after the close. For the quarter ended Sep 2026, ENTX reported EPS of $0.11 on revenue of $0. Over its last 8 reports the stock moved an average of 4.8% the session after earnings. Over the last 12 months ENTX insiders bought $141K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ENTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ENTX.

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$29.4M
Free cash flow
−$15.8M
Valuation
Market cap
$575.5M
174.1M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$265.9M
At Sep 30
Shareholder equity
$274.3M
Shares outstanding
174.1M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $571K$571KFY2021FY2022: $134K$134KFY2022FY2023: $0$0FY2023FY2024: $181K$181KFY2024FY2025: $42K$42KFY2025

From ENTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Mar 26
Estimated date · After the close
Reported EPS
$0.11
Quarter ended Sep 2026
Year ago EPS
$0.07
+57.1% on a GAAP basis
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.06Dec '24Mar 2025: $0.06Mar '25Jun 2025: $0.06Jun '25Sep 2025: $0.07Sep '25Dec 2025: $0.07Dec '25Mar 2026: $0.07Mar '26Jun 2026: $0.14Jun '26Sep 2026: $0.11Sep '26Latest $0.11
Revenue by quarter
Dec 2024: $82,000Dec '24Mar 2025: $42,000Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How ENTX moved after its last 8 reports
Average move the session after a report ±4.8%
Nov 6, 2026After the close+3.5%
Aug 7, 2026After the close+5.9%
May 8, 2026After the close−10.0%
Mar 27, 2026After the close−11.5%
Nov 14, 2025After the close−1.1%
Aug 8, 2025After the close+3.3%
May 9, 2025After the close0.0%
Mar 28, 2025After the close−2.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ENTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ENTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ENTX

Technical Analysis

ENTX · as of the Nov 20 close · updated each morning
Uptrend

The stock is 5% above its 20 day and 11% above its 50 day average. It is 38% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 61). The nearest support is the Pivot at $3.27, and the nearest resistance the Pivot R1 at $3.37.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityLow, 5.7%/day
Key levels
$4.2052 week high+26.9%
$3.49Swing high (Nov 9)+5.4%
$3.37Pivot R1+1.8%
$3.31Last close
$3.27Pivot−1.2%
$3.21Pivot S1−3.0%
$3.1320 day average−5.4%
$3.00Swing low (Nov 16)−9.4%
$2.9350 day average−11.5%
$2.78100 day average−16.0%
$2.03200 day average−38.7%
$0.9152 week low−72.5%
Indicators
RSI (14)61.13Strong, overbought above 70Neutral
MACD0.09Below its signal lineBearish
Stochastic64.9Middle of its rangeNeutral
ADX (14)30.5Trending up
Williams %R-31.1Oversold below −80, overbought above −20Neutral
CCI (20)123.0Oversold below −100, overbought above 100Overbought
Rate of change+5.3%Change over 10 sessionsBullish
ATR (14)$0.19Typical daily range, 5.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ENTX

What happened before

See how ENTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ENTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ENTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ENTXHow many large options trades hit ENTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ENTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲38 buying vs 8 selling
  • ▲Held by funds +67.5 pts
  • ▲Funds holding +19
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4627+70.4%
In funds' top 1041+300.0%
Held by funds73.7%6.2%+67.5 pts
New / increased24 / 147 / 8+153.3%
Reduced / sold out4 / 46 / 6−33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ENTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ENTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$141K8 buys · 5 insiders
Sold$00 sales · 0 insiders
Cluster buy: 4 insiders bought $121K between Feb 9 and Mar 9.
2025-12 bought $20K2026-02 bought $83K2026-03 bought $38KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 9Geno J GermanoDirectorBuy20,000$1.30$26K
Mar 5Sean EllisDirectorBuy10,000$1.23$12K
Feb 12Steven D RubinDirectorBuy5,000$1.49$7K
Feb 10Geno J GermanoDirectorBuy20,000$1.49$30K
Feb 10Haya TaitelDirectorBuy7,500$1.48$11K
Feb 9Sean EllisDirectorBuy18,000$1.24$22K
Every insider buy and sale for ENTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ENTX insider trades →

From SEC Form 4 filings by ENTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENTX is in one of them and how their past ENTX trades turned out.

ENTX in the AI portfolios
Loading…

ENTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ENTX in an article yet. Here's the latest on the wider market.

ENTX in the news

About Entera Bio

Entera Bio is a clinical stage company developing oral tablet versions of peptide and protein medicines that are usually given by injection. Its most advanced product candidate, EB613, is an oral form of teriparatide being studied as a treatment for osteoporosis, a condition that weakens bones and raises fracture risk. The company's N-Tab platform is designed to help these medicines survive digestion and pass into the bloodstream. Entera is based in Jerusalem and targets patients and healthcare providers.

Headquarters
Jerusalem